Dabigatran Etexilate Mesylate
6 NDCs across 1 manufacturer|0 Generic,6 Brand
Dabigatran Etexilate Mesylate is used to treat pulmonary embolism and venous thrombosis, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Oct 19, 2010, and the first generic was approved Mar 11, 2020. FDA's Orange Book lists 26 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $199 million on Dabigatran Etexilate Mesylate across 782,000 claims for 247,000 beneficiaries.
Dabigatran Etexilate Mesylate is available as 6 NDCs from 1 manufacturer (0 generic, 6 brand), with NADAC prices from $3.16 to $3.17 per EA — a 0% difference between cheapest and most expensive. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
6
0G / 6B
Manufacturers
1
competing in market
Price Spread
$3.16 – $3.17
per EA
7d Activity
avg +0.1% WoW · of 6 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Boehringer Ingelheim Pharmaceuticals Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Direct Thrombin Inhibitor class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
1 manufacturer producing DABIGATRAN ETEXILATE MESYLATE
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
PRADAXA 75 MG CAPSULE | $3.1670 per EA | +0.27% |
PRADAXA 75 MG CAPSULE | $3.1670 per EA | +0.27% |
PRADAXA 110 MG CAPSULE | $3.1665 per EA | — |
PRADAXA 110 MG CAPSULE | $3.1665 per EA | — |
PRADAXA 150 MG CAPSULE | $3.1597 per EA | -0.03% |
PRADAXA 150 MG CAPSULE | $3.1597 per EA | -0.03% |
Frequently Asked Questions
What is Dabigatran Etexilate Mesylate used to treat?
Dabigatran Etexilate Mesylate is used to treat pulmonary embolism and venous thrombosis, per the National Library of Medicine's MED-RT classification.
When did Dabigatran Etexilate Mesylate become available as a generic?
FDA approved the first generic Dabigatran Etexilate Mesylate (ANDA) on Mar 11, 2020. The Orange Book currently lists 26 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Dabigatran Etexilate Mesylate?
In 2024, Medicare Part D spent $199 million on Dabigatran Etexilate Mesylate across 782,000 claims for 247,000 beneficiaries.
How many Dabigatran Etexilate Mesylate products are on the market?
The Dabigatran Etexilate Mesylate drug market contains 6 NDCs from 1 manufacturer — 0 generic and 6 brand products.
What is the price range for Dabigatran Etexilate Mesylate?
NADAC reference prices for Dabigatran Etexilate Mesylate range from $3.1597 to $3.1670 per EA — a 0% difference between cheapest and most expensive.
Which manufacturers make Dabigatran Etexilate Mesylate?
1 manufacturer lists Dabigatran Etexilate Mesylate in NADAC. Ranked by number of NDCs, the largest are Boehringer Ingelheim Pharmaceuticals Inc. (6).
How has the price of Dabigatran Etexilate Mesylate changed recently?
Over the past 7 days, 2 Dabigatran Etexilate Mesylate NDCs rose and 2 fell, with a market-wide average change of +0.1%.